GlaxoSmithKline's Cervical Cancer Vaccine Protects Against Five Viruses, Study Shows
RESEARCH TRIANGLE PARK, N.C. - A study published Tuesday shows that a cervical cancer vaccine from drug giant GlaxoSmithKline (NYSE:GSK) is effective against not one but five of the most common viruses related to cancer.
Glaxo, which maintains its U.S. headquarters in RTP, paid for the study that was published in The Lancet.
The results show Cervarix is highly effective against the most common cervical cancer-causing virus types and has the potential to substantially reduce the incidence of cervical pre-cancers, cervical cancer and the associated diagnostic and surgical procedures, said professor Jorma Paavonen, from the University of Helsinki, Finland, the principal investigator of the study.
The results re-affirm confidence in vaccination as a primary preventative measure against cervical cancer when used alongside screening, he added.
GSK is seeking regulatory approval to sell Cervarix in the U.S. Cervarix is seen as a potential rival to Merck's Gardasil, which already is sold in the U.S. Cervarix produced more than $230 million in sales for GSK last year.
Add A New CommentWe value and respect the experiences of all of our HerWriters, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice although we hope you can gain knowledge from their insight.
Add A New CommentComments
There are no comments yet. Be the first to get the conversation started.